Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -7.45% | -- | 70.08% | -37.71% | -66.22% |
| Gross Profit | 7.45% | -- | -70.08% | 37.71% | -119.84% |
| SG&A Expenses | -21.52% | -20.45% | -10.86% | -34.59% | -53.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.82% | -20.91% | -22.12% | -34.58% | -62.48% |
| Operating Income | 13.82% | 20.91% | 22.12% | 34.58% | -158.30% |
| Income Before Tax | 24.21% | 199.33% | 54.96% | -24.43% | -156.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.21% | 199.33% | 54.96% | -24.43% | -156.27% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 2,144.32% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.60% | 181.43% | 62.09% | 285.51% | -170.61% |
| EBIT | 13.82% | 20.91% | 22.12% | 34.58% | -158.30% |
| EBITDA | 13.22% | 20.44% | 21.59% | 35.28% | -153.77% |
| EPS Basic | 47.66% | 168.35% | 71.21% | 255.91% | -159.52% |
| Normalized Basic EPS | 33.72% | 50.26% | 104.55% | -4.57% | -147.43% |
| EPS Diluted | 47.69% | 168.26% | 70.25% | 255.79% | -160.29% |
| Normalized Diluted EPS | 33.72% | 50.33% | 104.55% | -4.57% | -148.22% |
| Average Basic Shares Outstanding | 15.42% | 19.14% | 31.66% | 18.99% | 18.63% |
| Average Diluted Shares Outstanding | 15.42% | 19.30% | 31.66% | 18.99% | 16.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |